SOLV Stock Analysis: Solventum | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 15.242m USD | 12M Return: 17.8% | US83444M1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 73.0M
Qual. Beats: 2
Rev. Trend: 76.5%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solventum Corporation (NYSE: SOLV) is a U.S.-headquartered healthcare company that develops, manufactures, and commercializes a diverse portfolio of medical products and software solutions, operating through three reportable segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment supplies wound care, sterilization assurance, temperature management, and other hospital consumables, while Dental Solutions offers orthodontic and restorative products, and Health Information Systems provides software such as computer-assisted physician documentation, speech recognition, and coding automation. Solventum sells through direct-to-consumer, distribution, key account management, inside sales, and e-commerce channels, and was incorporated in 2023 and spun off/spun out for public trading in early 2024.
The company falls within the Health Care Equipment GICS sub-industry, a sector that includes manufacturers of medical devices, supplies, and health-care technology tools serving providers, payers, and patients. Solventums mix of single-use Medsurg consumables, recurring dental supply sales, and software-based Health Information Systems reflects a hybrid business model that combines hardware/medical product revenue with higher-margin, recurring software and services revenue.
- Medsurg wound care segment drives organic revenue growth
- Health Information Systems software scales on AI documentation demand
- Debt paydown from 3M spinoff pressures near-term margins
| Net Income: 1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -1.80 > 1.0 |
| NWC/Revenue: 0.94% < 20% (prev 7.01%; Δ -6.07% < -1%) |
| CFO/TA 0.01 > 3% & CFO 209.0m > Net Income 1.43b |
| Net Debt (5.09b) to EBITDA (2.47b): 2.06 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (174.4m) vs 12m ago -0.46% < -2% |
| Gross Margin: 54.69% > 18% (prev 54.52%; Δ 0.17% > 0.5%) |
| Asset Turnover: 56.69% > 50% (prev 55.65%; Δ 1.05% > 0%) |
| Interest Coverage Ratio: 7.38 > 6 (EBIT TTM 1.96b / Interest Expense TTM 266.0m) |
| A: 0.01 (Total Current Assets 3.74b - Total Current Liabilities 3.66b) / Total Assets 14.2b |
| B: 0.13 (Retained Earnings 1.90b / Total Assets 14.2b) |
| C: 0.13 (EBIT TTM 1.96b / Avg Total Assets 14.7b) |
| D: 0.51 (Book Value of Equity 4.80b / Total Liabilities 9.44b) |
| Altman-Z'' = 1.90 = BBB |
| DSRI: 1.15 (Receivables 1.43b/1.25b, Revenue 8.31b/8.39b) |
| GMI: 1.00 (GM 54.52% / 54.69%) |
| AQI: 0.90 (AQ_t 0.63 / AQ_t-1 0.70) |
| SGI: 0.99 (Revenue 8.31b / 8.39b) |
| TATA: 0.09 (NI 1.43b - CFO 209.0m) / TA 14.2b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of October 04, 2026, the stock is trading at USD 87.85 with a total of 878,618 shares traded. Over the past week, the price has changed by -1.84%, over one month by -4.41%, over three months by +12.24% and over the past year by +17.76%.
Current recommended Stop Loss: 85.30 (which is 2.9% or 1.3 ATR below the current price).
Solventum has received a consensus analysts rating of 3.25. Therefore, it is recommended to hold SOLV.
- StrongBuy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 93.9 | 6.9% |
P/E Trailing = 10.9462
P/E Forward = 13.089
P/S = 1.8342
P/B = 3.1345
P/EG = 1.2198
Revenue TTM = 8.31b USD
EBIT TTM = 1.96b USD
EBITDA TTM = 2.47b USD
Long Term Debt = 4.57b USD (from longTermDebt, last quarter)
Short Term Debt = 506.0m USD (from shortTermDebt, last quarter)
Debt = 5.49b USD (from shortLongTermDebtTotal, last quarter) + Leases 207.0m
Net Debt = 5.09b USD (calculated: Debt 5.49b - CCE 403.0m)
Enterprise Value = 20.3b USD (15.2b + Debt 5.49b - CCE 403.0m)
Interest Coverage Ratio = 7.38 (Ebit TTM 1.96b / Interest Expense TTM 266.0m)
EV/FCF = -172.3x (Enterprise Value 20.3b / FCF TTM -118.0m)
FCF Yield = -0.58% (FCF TTM -118.0m / Enterprise Value 20.3b)
FCF Margin = -1.42% (FCF TTM -118.0m / Revenue TTM 8.31b)
Net Margin = 17.26% (Net Income TTM 1.43b / Revenue TTM 8.31b)
Gross Margin = 54.69% ((Revenue TTM 8.31b - Cost of Revenue TTM 3.77b) / Revenue TTM)
Gross Margin QoQ = 58.22% (prev 54.66%)
Tobins Q-Ratio = 1.43 (Enterprise Value 20.3b / Total Assets 14.2b)
Interest Expense / Debt = 4.84% (Interest Expense 266.0m / Debt 5.49b)
Taxrate = 15.39% (261.0m / 1.70b)
NOPAT = 1.66b (EBIT 1.96b * (1 - 15.39%))
Current Ratio = 1.02 (Total Current Assets 3.74b / Total Current Liabilities 3.66b)
Debt / Equity = 1.14 (Debt 5.49b / totalStockholderEquity, last quarter 4.80b)
Debt / EBITDA = 2.06 (Net Debt 5.09b / EBITDA 2.47b)
Debt / FCF = -43.14 (negative FCF - burning cash) (Net Debt 5.09b / FCF TTM -118.0m)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.78% (Net Income 1.43b / Total Assets 14.2b)
RoE = 28.96% (Net Income TTM 1.43b / Total Stockholder Equity 4.95b)
RoCE = 20.60% (EBIT 1.96b / Capital Employed (Equity 4.95b + L.T.Debt 4.57b))
RoIC = 15.54% (NOPAT 1.66b / Invested Capital 10.7b)
WACC = 6.85% (E(15.2b)/V(20.7b) * Re(7.84%) + D(5.49b)/V(20.7b) * Rd(4.84%) * (1-Tc(0.15)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.50 | Cagr: 0.43%
[DCF] Fair Price = unknown (Cash Flow -118.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 2
Revenue Correlation: 76.53 | Revenue CAGR: 0.84% | SUE: 3.23 | # QB: 5
EPS current Quarter (2026-09-30): EPS=1.35 | Chg30d=+0.30% | Revisions=-64% | Analysts=11
EPS current Year (2026-12-31): EPS=7.14 | Chg30d=-0.54% | Revisions=+82% | GrowthEPS=+16.9% | GrowthRev=-1.1%
EPS next Year (2027-12-31): EPS=7.23 | Chg30d=+0.13% | Revisions=+47% | GrowthEPS=+1.2% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +31% (up=26, down=13)